The European Commission has approved RASONQUE (daraxonrasib), a targeted cancer medicine developed by Revolution Medicines, for patients with metastatic pancreatic adenocarcinoma. The approval marks a milestone in advanced pancreatic cancer treatment, offering an alternative to chemotherapy, especially for patients whose cancer has progressed despite earlier treatment.RASONQUE is an oral medication which is taken once daily. It is the first broad RAS-targeted medicine approved in Europe for metastatic pancreatic cancer and can be used in patients with or without an identified RAS tumour mutation.The approval applies to all European Union member states and the European Economic Area countries Iceland, Norway and Liechtenstein. It does not extend to the UK or Switzerland, which have separate regulatory approval processes.More About RASONQUE Pancreatic adenocarcinoma, the most common form of pancreatic cancer, is driven by alterations in the RAS genes. These genes produce proteins that are involved in regulating cell growth. When mutations keep RAS proteins active, they can drive uncontrolled cancer cell growth.Around 147,000 people are diagnosed with pancreatic cancer in Europe each year. The five-year survival rate is also below 10%. As early-stage pancreatic cancer shows few or no symptoms, approximately 80% of patients are diagnosed after the disease has spread.Daraxonrasib works by blocking RAS proteins, which can become overactive in cancer cells and send signals that tell them to grow and multiply. It binds to a protein called cyclophilin A to form a complex that attaches to these active RAS proteins, preventing them from sending growth signals. This helps stop the cancer cells from growing and spreading. Unlike treatments that target a single RAS mutation, daraxonrasib inhibits multiple RAS variants.Also read: Bowel, Pancreatic & Liver: NHS Trial Offers New Blood Test To 20,000 Patients That Could Detect 13 CancersWhat Did The Clinical Trial Find?The European Commission's decision was based on results from the Phase 3 RASolute 302 trial, which compared daraxonrasib with standard chemotherapy in 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma. Approximately 92% of participants had confirmed RAS G12 mutations.According to the European Medicines Agency (EMA), patients receiving daraxonrasib had a median overall survival of 12.4 months, compared to 6.7 months among those receiving chemotherapy.Median progression-free survival, which measures how long patients live without their disease worsening, was 7.2 months with daraxonrasib versus 3.6 months with chemotherapy.The US Food and Drug Administration (FDA), which approved the drug in August 2026, also reported improvements in overall survival and progression-free survival in both patients with RAS G12 mutations and the overall trial population.Also read: New Pancreatic Cancer Vaccine Triggers Immune Response In 99% Of PatientsWhat Are The Side Effects?The most commonly reported side effects of daraxonrasib include diarrhoea, skin rash, stomatitis (inflammation of the mouth lining), nausea and vomiting.The drug also carries warnings for serious complications like severe skin and soft tissue reactions, gastrointestinal perforation and interstitial lung disease or pneumonitis. Although the European Commission has granted approval, patient access will depend on individual countries completing their pricing, health technology assessment and reimbursement processes.Revolution Medicines said it is working with healthcare systems and relevant stakeholders across Europe to enable access to the treatment.The approval follows an expedited assessment under the EMA's Cancer Medicines Pathfinder project, which aims to accelerate the evaluation of promising medicines addressing significant unmet medical needs.